Three New Immunotherapy Agents Tested Against Melanoma in Phase 2 Clinical Trials
Several new agents designed to reactivate the immune system were tested in combination with FDA-approved immunotherapies, as reported in data…
Blog - Melanoma360
06/05/2025
Three New Immunotherapy Agents Tested Against Melanoma in Phase 2 Clinical Trials
Several new agents designed to reactivate the immune system were tested in combination with FDA-approved immunotherapies, as reported in data…
|
06/05/2025
Genetic Test a Potential Alternative to Sentinel Lymph Node Biopsy
There may be a non-invasive option available for patients with head and neck melanoma who cannot easily receive a sentinel…
|
06/05/2025
New Therapy in Clinical Trial Returns Immunotherapeutic Activity to Resistant Melanoma
A group in Italy may have found a way to revive the response to immunotherapy in patients who have developed…
|
06/05/2025
Early Clinical Trial Shows Drug Activity to Work in Patients with Acral and Mucosal Melanoma
Results of a Phase 1/2 clinical trial showed promising data for patients with advanced acral and mucosal melanoma. The results…
|
06/05/2025
Results Prove Immunotherapy Should be the Initial Treatment for BRAF Mutant Tumors
Five-year clinical trial results presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago confirmed…
|
06/03/2025
Trial Result Confirms the Advantage of Cemiplimab for Skin Cancer at High Risk of Recurrence
We usually don’t feature nonmelanoma skin cancer articles here, but we thought you might be interested in what’s happening in…
|
05/28/2025
Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications
News provided byHalozyme Therapeutics, Inc. May 28, 2025, 08:30 ET Opdivo® is the first and only PD-1 inhibitor approved for subcutaneous (SC)…
|
|
05/14/2025
Parenting Through Cancer
In this deeply personal episode, Drs. Samantha and Samuel Siegel share their journey of navigating cancer, medical school, and family…
|
05/09/2025
Tri-State Melanoma Consortium – Inaugural Convening
Last night, leading melanoma researchers and clinicians from across the New York , New Jersey, and Connecticut region gathered at…
|
05/01/2025
AIM at Melanoma + WEARSPF®: Partnering for a Cause This Melanoma Awareness Month
May is Melanoma Awareness Month—a time to come together, raise awareness, and take meaningful steps toward ending one of the…
|
Recent Posts
Sep. 05, 2025
Advocating for Patients: Letter to the FDA on RP1 Treatment Access
Sep. 04, 2025
Hope on the Horizon: Clinical Trials & Progress in Ocular/Uveal Melanoma
Aug. 26, 2025
Back to AIM: Advocacy, Walks, and Fall Initiatives in Melanoma
Aug. 26, 2025
Side Effect Central – Cutaneous Squamous Cell Carcinoma and Keratoacanthoma
Aug. 26, 2025